Companion Animal Vaccines Market Size, Share and Global Trend By Animal Type (Canine, Feline, Equine, Avian), By Vaccine Type (Attenuated Live Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant, Conjugate & Sub-unit Vaccines), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Stores) and Regional Forecast, 2024-2032

Companion animal vaccines are one of the most effective and critical intervention for preventing companion animal diseases and for promoting animal health and welfare, safe food production and public health. Companion animal vaccines play a crucial role in animal health protection by preventing and controlling serious epizootic diseases. Most of the veterinary vaccines are administered through oral or parenteral routes of administration.

Campanion animal vaccines also plays a crucial role in preventing the spread of diseases to humans. Many clinical studies are undertaken to develop vaccines for various animal diseases using new vaccine technologies such as marker vaccine, split –product, isolated protein or peptide and nucleic acid approaches. Furthermore, companion animval vaccine industry has paved its way for many key mergers and acquisitions. For example, in October 2016, Elanco, a subsidiary company of Eli Lilly and Company acquired the U.S. canine, feline and rabies animal vaccines product portfolio of Boehringer Ingelheim, one of the major players in animal health.

Global companion animal vaccines market growth is being driven by the rise in number of pet owner, increased episodes of disease outbreaks, increased use and demand of biotechnology in production of recombinant vaccine, DNA vaccines, multivalent vaccines and others. In addition, the increased government initiatives to prevent the spread of zoonotic diseases through guidelines and awareness programs are also expected to fuel the growth of global animal vaccines market during the forecast period.

However, the strict government guidelines and high cost in proper storage of vaccines are the factors that are anticipated to hinder the growth of global animal vaccines market.

Key Players Covered

The major companies covered in the global companion animal vaccines market report include Bayer AG, Heska, Zoetis, Intervet Inc. (Merck Animal Health), Ceva, Boehringer Ingelheim International GmbH, Vetoquinol S.A., Elanco, and Virbac.

SEGMENTATION

As per the current companion animal vaccines market trends, canine vaccine segment among the animal type is anticipated to account for the maximum market share owing to the increase in number of pet owners and rising prevalence of rabies among dogs. According to the American Pet Products Association, 60.2 million households in the U.S owned a dog during 2017-2018, making it the most common pet in the U.S., which is anticipated to fuel the demand for canine vaccines.

Key Insights

• Epidemiology of companion animal diseases for key countries


• Pipeline analysis


• New product launches


• Advancements in vaccine production technology


• Key mergers and acquisitions 

Regional Analysis:

Geographically, the global companion animal vaccines market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the global companion animal vaccines during the forecast years owing to the increasing number of per owner, active investment of animal health and increased research. According to the American Pet Products Association, a total of 393. Mn pet were owned in the U.S. during 2017-2018, which is likely to favour the demand for companion animal vaccines in North America. The emerging government recommendations and guidelines on animal vaccines, technological advancement in animal vaccine production and strategic collaborations. The companion animal vaccines market in Asia Pacific, Latin America, Middle East and Africa is projected to expand primarily due to the improved distribution channels in these regions, improving health reforms and awareness on animal health.

Companion Animal Vaccines Industry Developments

• In March 2019, Virbac announced the availability of CANILEISH, a vaccine against canine leishmaniosis in Turkey.
• In December 2018, Phibro Animal Health, a company focused on animal health and nutrition acquired assets of KoVax in order to strengthen its position in fish vaccines.
• In October 2016, Elanco, a subsidiary company of Eli Lilly and Company acquired the U.S. canine, feline and rabies animal vaccines portfolio of Boehringer Ingelheim